Amylin Pharmaceuticals and Lilly have agreed to the terms of a joint supply agreement for a pen device for exenatide once-weekly. The two companies have each initiated a Phase I/II clinical study for a new exenatide once-weekly suspension formulation. Amylin and Lilly have agreed to develop, manufacture and market the drug in a dual chamber cartridge pen device. This design will enable patients to mix and administer the drug from a pre-filled pen, instead of the syringe and vial currently use...